Market revenue in 2023 | USD 1,534.5 million |
Market revenue in 2030 | USD 2,606.3 million |
Growth rate | 7.9% (CAGR from 2023 to 2030) |
Largest segment | Ferric carboxymaltose |
Fastest growing segment | Ferric Carboxymaltose |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Iron Dextran, Iron Sucrose, Ferric Carboxymaltose |
Key market players worldwide | AbbVie Inc, Civitas Resources Inc Ordinary Shares, Daiichi Sankyo Co Ltd, Sanofi SA, CSL Ltd, COSMOS Pharmaceutical Corp, Zydus Lifesciences, Rockwell Medical Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to intravenous iron drugs market will help companies and investors design strategic landscapes.
Ferric carboxymaltose was the largest segment with a revenue share of 44.99% in 2023. Horizon Databook has segmented the North America intravenous iron drugs market based on iron dextran, iron sucrose, ferric carboxymaltose covering the revenue growth of each sub-segment from 2018 to 2030.
In 2022, North America held a substantial share of the Intravenous (IV) iron drugs market, primarily due to the increasing approvals and launch of new IV drugs in the U.S. For instance, in December 2021, American Regent, Inc. and Daiichi Sankyo, Inc. disclosed that the U.S. FDA granted approval for Injective for pediatric patients with Iron Deficiency Anemia (IDA) who are insensitive to oral iron or who have exhibited an inadequate response to receiving oral iron.
These patients must be at least a year old. The suggested dosage for patients weighing below 50 kg is two intravenous doses of Injective 15 mg/kg body weight at least 7 days apart for each course. North America held a dominant share of the market, which can be attributed to increasing prevalence of cancer, Chronic Kidney Disease (CKD), and gastrointestinal disorders in the region.
For instance, according to the International Agency for Research on Cancer (IARC), over 20.7 million new cancer cases are expected to be diagnosed in 2023. Furthermore, increasing awareness about women’s health and rising prevalence of celiac diseases are also some of the other factors driving the regional market growth.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America intravenous iron drugs market , including forecasts for subscribers. This continent databook contains high-level insights into North America intravenous iron drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account